Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by COLQ Mutations.

Current neuropharmacology - 1 Jan 2023

Shao Shuai, Shi Guanzhong, Bi Fang-Fang, Huang Kun

Abstract excerpt

BACKGROUND: Congenital myasthenic syndromes (CMS) refer to a series of inherited disorders caused by defects in various proteins. Mutation in the collagen-like tail subunit of asymmetric acetylcholinesterase (COLQ) is the second-most common cause of CMS. However, data on pharmacological treatments are limited. OBJECTIVE: In this study, we reviewed related reports to determine the most appropriate pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcholinesterase
Share to Adrenergic beta-Agonists
Share to Collagen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle Proteins

Share to Mutation

Share to Myasthenic Syndromes, Congenital

Source

Open in PubMed Open full text

Identifiers

PMID: 36703579
DOI: 10.2174/1570159X21666230126145652
PMCID: PMC10472815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by COLQ Mutations.PMID 36703579Read ↗

Pharmacological Strategy for Congenital Myasthenic Syndrome with CHRNE Mutations: A Meta-Analysis of Case Reports.Semantic proximity Read ↗

COLQ-Congenital myasthenic syndrome in an Iranian cohort: the clinical and genetics spectrum.Semantic proximity Read ↗

Therapeutic strategies for congenital myasthenic syndromes.Semantic proximity Read ↗

The First Case of Congenital Myasthenic Syndrome Caused by a Large Homozygous Deletion in the C-Terminal Region of COLQ (Collagen Like Tail Subunit of Asymmetric Acetylcholinesterase) Protein.Semantic proximity Read ↗

Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.Semantic proximity Read ↗

First characterization of congenital myasthenic syndrome type 5 in North Africa.Semantic proximity Read ↗

[Studies on therapeutic strategies for congenital myasthenic syndromes.]Semantic proximity Read ↗

Congenital myasthenic syndromes: genetic defects of the neuromuscular junction.Semantic proximity Read ↗

Synaptic congenital myasthenic syndrome in three patients due to a novel missense mutation (T441A) of the COLQ gene.Semantic proximity Read ↗

Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic).Semantic proximity Read ↗

Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations.Semantic proximity Read ↗

A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.